{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T02:35:36Z","timestamp":1792550136578,"version":"4.5.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":2041,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1124\/jpet.119.257311","type":"journal-article","created":{"date-parts":[[2019,4,2]],"date-time":"2019-04-02T22:48:35Z","timestamp":1554245315000},"page":"443-453","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Translation of Inhaled Drug Optimization Strategies into Clinical Pharmacokinetics and Pharmacodynamics Using GSK2292767A, a Novel Inhaled Phosphoinositide 3-Kinase \u03b4 Inhibitor"],"prefix":"10.1016","volume":"369","author":[{"given":"Malcolm","family":"Begg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris D","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Nicole","family":"Hamblin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Pefani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Vitulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Mallett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josie","family":"Morrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin I","family":"Hingle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sorif","family":"Uddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filzah","family":"Ehtesham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Marotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Harrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla F","family":"Newman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Disala","family":"Fernando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Cahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith M","family":"Hessel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.119.257311_bib1","doi-asserted-by":"crossref","DOI":"10.1124\/jpet.118.255109","article-title":"Relationship between pharmacokinetics and pharmacodynamic responses in healthy smokers informs a once daily dosing regimen for nemiralisib","author":"Begg","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.119.257311_bib2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.pupt.2017.08.008","article-title":"Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3K\u03b4 inhibitor under development for the treatment of COPD","volume":"46","author":"Cahn","year":"2017","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1124\/jpet.119.257311_bib23","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nmeth.1564","article-title":"Quantification of PtdInsP3 molecular species in cells and tissues by mass spectrometry","volume":"8","author":"Clark","year":"2011","journal-title":"Nat Methods"},{"key":"10.1124\/jpet.119.257311_bib3","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2174\/138920012800166571","article-title":"Optimisation of DMPK by the inhaled route: challenges and approaches","volume":"13","author":"Cooper","year":"2012","journal-title":"Curr Drug Metab"},{"key":"10.1124\/jpet.119.257311_bib4","doi-asserted-by":"crossref","first-page":"34424","DOI":"10.1038\/srep34424","article-title":"Cigarette smoke reversibly activates hypoxia-inducible factor 1 in a reactive oxygen species-dependent manner","volume":"6","author":"Daijo","year":"2016","journal-title":"Sci Rep"},{"key":"10.1124\/jpet.119.257311_bib5","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0378-5173(03)00091-7","article-title":"A novel method for assessing dissolution of aerosol inhaler products","volume":"255","author":"Davies","year":"2003","journal-title":"Int J Pharm"},{"key":"10.1124\/jpet.119.257311_bib6","doi-asserted-by":"crossref","first-page":"7381","DOI":"10.1021\/acs.jmedchem.5b00767","article-title":"Optimization of novel indazoles as highly potent and selective inhibitors of phosphoinositide 3-kinase \u03b4 for the treatment of respiratory disease","volume":"58","author":"Down","year":"2015","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.119.257311_bib7","doi-asserted-by":"crossref","first-page":"6640","DOI":"10.1021\/jm1005989","article-title":"Inhalation by design: novel ultra-long-acting \u03b22-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup","volume":"53","author":"Glossop","year":"2010","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.119.257311_bib8","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1023\/A:1016259225244","article-title":"Assessment of glucocorticoid lung targeting by ex-vivo receptor binding studies in rats","volume":"12","author":"Hochhaus","year":"1995","journal-title":"Pharm Res"},{"key":"10.1124\/jpet.119.257311_bib9","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/j.1552-4604.1997.tb04262.x","article-title":"Pharmacokinetic\/pharmacodynamic aspects of aerosol therapy using glucocorticoids as a model","volume":"37","author":"Hochhaus","year":"1997","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/jpet.119.257311_bib10","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/bdd.325","article-title":"Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery","volume":"23","author":"Kalvass","year":"2002","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/jpet.119.257311_bib11","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1124\/jpet.118.249516","article-title":"A multicentre, randomized, double-blind, placebo-controlled, crossover study to investigate the efficacy, safety, tolerability, and pharmacokinetics of repeat doses of inhaled nemiralisib in adults with persistent, uncontrolled asthma","volume":"367","author":"Khindri","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.119.257311_bib12","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/jat.2950","article-title":"Foamy macrophage responses in the rat lung following exposure to inhaled pharmaceuticals: a simple, pragmatic approach for inhaled drug development","volume":"34","author":"Lewis","year":"2014","journal-title":"J Appl Toxicol"},{"key":"10.1124\/jpet.119.257311_bib13","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1046\/j.1365-2125.1996.00493.x","article-title":"Pharmacokinetics of inhaled drugs","volume":"42","author":"Lipworth","year":"1996","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl A","key":"10.1124\/jpet.119.257311_bib14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0954-6111(97)90103-7","article-title":"Local versus systemic effects of inhaled drugs","volume":"91","author":"L\u00f6tvall","year":"1997","journal-title":"Respir Med"},{"key":"10.1124\/jpet.119.257311_bib15","doi-asserted-by":"crossref","first-page":"953","DOI":"10.2116\/analsci.25.953","article-title":"Live single-cell mass spectrometry","volume":"25","author":"Masujima","year":"2009","journal-title":"Anal Sci"},{"key":"10.1124\/jpet.119.257311_bib17","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3109\/01480545.2011.648327","article-title":"Regulatory toxicology considerations for the development of inhaled pharmaceuticals","volume":"36","author":"Owen","year":"2013","journal-title":"Drug Chem Toxicol"},{"key":"10.1124\/jpet.119.257311_bib18","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1021\/acs.jmedchem.7b00401","article-title":"Design and synthesis of soluble and cell-permeable PI3K\u03b4 inhibitors for long-acting inhaled administration","volume":"60","author":"Perry","year":"2017","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.119.257311_bib19","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1208\/s12249-012-9822-3","article-title":"Challenges with developing in vitro dissolution tests for orally inhaled products (OIPs)","volume":"13","author":"Riley","year":"2012","journal-title":"AAPS PharmSciTech"},{"key":"10.1124\/jpet.119.257311_bib20","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.coph.2015.05.017","article-title":"PI3K inhibitors in inflammation, autoimmunity and cancer","volume":"23","author":"Stark","year":"2015","journal-title":"Curr Opin Pharmacol"},{"key":"10.1124\/jpet.119.257311_bib21","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.drudis.2018.05.017","article-title":"Current approaches to the discovery of novel inhaled medicines","volume":"23","author":"Strong","year":"2018","journal-title":"Drug Discov Today"},{"key":"10.1124\/jpet.119.257311_bib22","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1164\/rccm.200906-0937OC","article-title":"Targeting phosphoinositide-3-kinase-\u03b4 with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease","volume":"182","author":"To","year":"2010","journal-title":"Am J Respir Crit Care Med"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652426002X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652426002X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.119.257311","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T16:00:35Z","timestamp":1739980835000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002235652426002X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S002235652426002X"],"URL":"https:\/\/doi.org\/10.1124\/jpet.119.257311","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Translation of Inhaled Drug Optimization Strategies into Clinical Pharmacokinetics and Pharmacodynamics Using GSK2292767A, a Novel Inhaled Phosphoinositide 3-Kinase \u03b4 Inhibitor","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.119.257311","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s).","name":"copyright","label":"Copyright"}]}}